ClinicalTrials.gg
Active, not recruitingNCT06007690CoMpassUpdated Oct 13, 2026

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

A Phase 3 interventional study of Bel-sar and Suprachoroidal Microinjector in Choroidal Melanoma, Indeterminate Lesions and Uveal Melanoma, sponsored by Aura Biosciences. Active, not recruiting at 53 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Aura Biosciences · Phase 3, Interventional, and Treatment

How we know

Updated Oct 13, 20261 site added14 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Uveal Melanoma with a site in United States — 26 open to participants now, 51 under way, 7 of them phase 3. Uveal Melanoma · United States.

Enrollment
25th of 163
108 · median 36
Started
2023
with 6 others
Phase 3
10 of 191
3 open now
Primary completion
2027-11
later than 29 of 50 live
Registered
169th of 191
by date
Lead sponsor
6 of 191
Aura Biosciences

Among the 191 studies in Uveal Melanoma with a site in United States, this one is the 25th largest by enrollment of the 163 interventional ones that give a count, is one of 7 that started in 2023, is one of 10 in phase 3, reaches primary completion later than 29 of the 50 other live ones, and was the 169th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

26 of the 191 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

Read the detailed description

This is a randomized, sham-controlled, subject-, assessor-, and Sponsor- masked trial to establish the safety and efficacy of bel-sar treatment via suprachoroidal (SC) administration in subjects with primary IL/CM. Bel-sar treatment incorporates administration of bel-sar drug product using a suprachoroidal space (SCS) microinjector and activation of bel-sar by a laser photoactivation device.

03

Conditions studied

  • Choroidal Melanoma
  • Indeterminate Lesions
  • Uveal Melanoma
  • Ocular Melanoma

Keywords

  • Uveal Melanoma
  • Eye Cancer
  • Ocular Melanoma
  • Choroidal Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)
  • Have no evidence of disease confirmed by imaging
  • Be treatment naive for IL/CM (subjects who received PDT may be eligible)

Exclusion criteria

Exclusion Criteria:

  • Have known or sensitivities to the study drug or laser
  • Active ocular infection or disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    High dose bel-sar treatment arm & laser application

    High dose of bel-sar + laser application

    Drug: Bel-sar · Device: Suprachoroidal Microinjector · Device: Infrared Laser

  • Experimental
    Low dose bel-sar treatment arm & laser application

    Low dose of bel-sar + laser application

    Drug: Bel-sar · Device: Suprachoroidal Microinjector · Device: Infrared Laser

  • Sham comparator
    Sham control arm & sham laser

    Sham injection + sham laser

    Device: Sham Infrared Laser · Device: Sham Microinjector

Interventions

  • DrugBelzupacap sarotalocanStudies of Belzupacap sarotalocanBelzupacap sarotalocan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Bel-sar via suprachoroidal administration followed by laser application.

    Also known as: AU-011

  • DeviceSuprachoroidal Microinjector

    Suprachoroidal injection device

    Also known as: SCS Microinjector

  • DeviceInfrared Laser

    Laser application

  • DeviceSham Infrared Laser

    Sham laser application

  • DeviceSham Microinjector

    Sham injection device

06

What researchers measure

Primary outcomes

  1. Time to reach tumor progression

    Tumor Progression

    Time frame: 65 weeks

Secondary outcomes

  1. Time to composite endpoint

    Tumor progression or visual acuity failure

    Time frame: 65 weeks

07

Study locations

53 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Nov 2027, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 23, 2023
StartActual
Dec 6, 2023
Primary completionEst.
Nov 15, 2027
CompletionEst.
Aug 15, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 14 sites removed
Show site
  • Eye Cancer Associates of Texas · Houston, United States
Show 14 removed
  • UCSD Shiley Eye Institute, Jacobs Retina Center · La Jolla, United States
  • Retina Associates of Florida, PA · Tampa, United States
  • Washington University · St Louis, United States
  • Nebraska Medicine's Truhlsen Eye Institute · Omaha, United States
  • Southeastern Retina Associates · Chattanooga, United States
  • Retina Associates of South Texas, P.A. · San Antonio, United States
  • Retina Consultants of Texas · The Woodlands, United States
  • Pacific NW Retina · Burlington, United States
  • UZ Leuven · Leuven, Belgium
  • Centre Hospitalier de l'Universite Laval · Québec, Canada
  • University Hospital Cologne (AöR) · Cologne, Germany
  • Universitätsklinikum Schleswig-Holstein Klinik für Augenheilkunde · Lübeck, Germany
  • Universitätsklinikum Tübingen · Tübingen, Germany
  • Hadassah Medical Center, Ein-Karem · Jerusalem, Israel
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added, 14 sites removed
    Show site
    • Eye Cancer Associates of Texas · Houston, United States
    Show 14 removed
    • UCSD Shiley Eye Institute, Jacobs Retina Center · La Jolla, United States
    • Retina Associates of Florida, PA · Tampa, United States
    • Washington University · St Louis, United States
    • Nebraska Medicine's Truhlsen Eye Institute · Omaha, United States
    • Southeastern Retina Associates · Chattanooga, United States
    • Retina Associates of South Texas, P.A. · San Antonio, United States
    • Retina Consultants of Texas · The Woodlands, United States
    • Pacific NW Retina · Burlington, United States
    • UZ Leuven · Leuven, Belgium
    • Centre Hospitalier de l'Universite Laval · Québec, Canada
    • University Hospital Cologne (AöR) · Cologne, Germany
    • Universitätsklinikum Schleswig-Holstein Klinik für Augenheilkunde · Lübeck, Germany
    • Universitätsklinikum Tübingen · Tübingen, Germany
    • Hadassah Medical Center, Ein-Karem · Jerusalem, Israel
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06007690
Lead sponsor
Aura Biosciences
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Dec 6, 2023
Primary completion
Nov 15, 2027 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Medical Monitor
study director · Aura Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belzupacap sarotalocan

Start the discussion